Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT03113422||Recruiting||Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy||
||Other / Industry||
||56||All||18 Years and older (Adult, Older Adult)||NCT03113422||PrE0403
|PrE0403||December 27, 2017||April 2022||November 2022||April 13, 2017||June 13, 2019||